These novel, targeted agents combine the unique, high specificity, properties and anti-tumor activity of monoclonal antibodies (mAbs) that are tumor-specific but not sufficiently cytotoxic, with the potent cell killing activity of cytotoxic small molecule drugs that are too toxic to be used on their own.
Because the process involves the expansion and purification of mAb-based proteins, ADC bioprocessing begins with the same workflow for regular protein therapeutics. After this phase, further steps are taken for ADC development.
Drug is chemically linked to the purified antibody
Tangential flow filtration
Concentration and Diafiltration
Fill / Finish